Login to Your Account

Pharma: Clinic Roundup

Monday, May 7, 2012

• Pfizer Inc., of New York, said a Phase IIIb withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary endpoint, defined as the change in mean pain score relative to baseline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription